Get the latest news source for local headlines from Nebraska Note. Covering politics, education, crime, health and more.

Nuropod Publishes Guide On Vagus Nerve Stimulation Devices For Anxiety Support

Nov 19, 2026

As the vagus nerve stimulation device market expands, Nuropod has published a guide examining three factors consumers can consider when evaluating devices for anxiety support: the evidence behind the technology, the stimulation delivery method, and whether the design supports consistent daily use.

-- With 12.5% of U.S. adults reporting regular feelings of worry, nervousness, or anxiety, according to the CDC’s 2025 National Health Interview Survey, Nuropod, maker of an auricular vagus nerve stimulation device, has published a guide examining the factors consumers can consider when evaluating vagus nerve stimulation devices for anxiety support.

Growing interest in noninvasive nervous system wellness has brought more devices into the category, making it harder to judge what separates one option from another. The guide argues that the distinction is less about broad calming claims and more about the evidence behind the technology, where and how stimulation is delivered, and whether the device can realistically fit into regular use.

Research quality is the first criterion the guide highlights. While a growing number of products are described as science-backed, the guide encourages consumers to look more closely at whether supporting research is peer-reviewed and placebo-controlled, and whether it is connected to the specific technology used in the device.

One published example is a single-blind randomized controlled trial by Jackowska et al., published in Biological Psychology in 2025. The study found that active transcutaneous vagus nerve stimulation produced superior effects to sham stimulation for anxiety symptoms and perceived stress in early-phase participants.

“When people struggle to relax, rest adequately and recover from stressful events, it might be a sign the body has become less resilient,” said Dr. Elisabetta Burchi, Translational Research Lead at Parasym. “Gentle, consistent support for the vagus nerve is one approach people are increasingly exploring as part of their wellness routines.”

Placement is another key distinction the guide raises. Vagus nerve stimulation devices may target the neck or the outer ear, with the delivery point shaping both device design and user experience. Nuropod uses Parasym’s AVNT™ waveform delivered through a small earpiece positioned on the tragus, the part of the outer ear where a branch of the vagus nerve reaches the skin.

The guide acknowledges that other devices address these criteria differently. Neck-based devices such as those targeting the cervical vagus nerve can achieve deeper stimulation and are supported by their own body of research, but typically require stronger intensity and more precise placement, which the guide notes can make them less practical for relaxed, everyday use. Some ear-based devices use the cymba conchae rather than the tragus as the stimulation point, a placement difference that reflects ongoing variation in research protocols across the field.

Against those criteria, the guide presents Nuropod as a wearable implementation of Parasym’s AVNT™ technology. The device is designed for sessions of around 30 minutes, once or twice a day, and can be used during everyday activities such as working, reading, or watching television.

Nuropod’s technology draws on more than a decade of Parasym research into auricular vagus nerve stimulation. Parasym reports more than 60 completed studies, more than 150 research collaborations, and more than five million neuromodulation sessions involving its technology.

For consumers comparing options, the guide places the emphasis on the quality of evidence behind the stimulation technology, how the device delivers that stimulation, and whether its design makes consistent daily use realistic.

About Parasym

Founded in 2015 and based in London, Parasym Scientific is a neurotechnology company developing noninvasive vagus nerve stimulation technology. Nuropod is Parasym’s North American wellness device, launched in the United States on September 5, 2025.

Additional information can be found at https://nuropod.com

Disclaimer: Research referenced in this article was conducted using Parasym's neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as guaranteed individual outcomes. Nuropod is classified by the FDA as a non-significant risk device and is not intended to diagnose, treat, cure, or prevent any disease.

Contact Info:
Name: PR Team
Email: Send Email
Organization: Nuropod by Parasym
Address: 2108 N Street, Sacramento, California 95816, United States
Website: https://nuropod.com/

Source: PressCable

Release ID: 89210200

If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release, or if there is a need for a press release takedown, we urge you to notify us without delay at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond within 8 hours – ensuring swift resolution of identified issues or offering guidance on removal procedures. Delivering accurate and reliable information is fundamental to our mission.

Looking for Local Media Coverage in the United States of America?

We have a place for all 50 States at the State News Network

What's Hot

More News

Press Releases